JP5732036B2 - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP5732036B2 JP5732036B2 JP2012500308A JP2012500308A JP5732036B2 JP 5732036 B2 JP5732036 B2 JP 5732036B2 JP 2012500308 A JP2012500308 A JP 2012500308A JP 2012500308 A JP2012500308 A JP 2012500308A JP 5732036 B2 JP5732036 B2 JP 5732036B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- heteroaryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 169
- 125000003118 aryl group Chemical group 0.000 claims description 91
- 125000001424 substituent group Chemical group 0.000 claims description 85
- 125000001072 heteroaryl group Chemical group 0.000 claims description 83
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims description 62
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 55
- -1 cyano, hydroxyl Chemical group 0.000 claims description 53
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 50
- 108091000080 Phosphotransferase Proteins 0.000 claims description 47
- 102000020233 phosphotransferase Human genes 0.000 claims description 47
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 30
- 229920006395 saturated elastomer Polymers 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 23
- 239000000460 chlorine Substances 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 239000011593 sulfur Substances 0.000 claims description 16
- 229910052763 palladium Inorganic materials 0.000 claims description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 13
- 125000002541 furyl group Chemical group 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 10
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 239000007822 coupling agent Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- ANVUICNGPOHXRE-UHFFFAOYSA-N C1(=CC=CC=C1)P(C1=CC=CC=C1)[C-]1C=CC=C1.[CH-]1C=CC=C1.[Fe+2].Cl.Cl Chemical compound C1(=CC=CC=C1)P(C1=CC=CC=C1)[C-]1C=CC=C1.[CH-]1C=CC=C1.[Fe+2].Cl.Cl ANVUICNGPOHXRE-UHFFFAOYSA-N 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 259
- 239000000543 intermediate Substances 0.000 description 218
- 239000000203 mixture Substances 0.000 description 158
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 150
- 238000005481 NMR spectroscopy Methods 0.000 description 136
- 239000007787 solid Substances 0.000 description 101
- 235000019439 ethyl acetate Nutrition 0.000 description 99
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 88
- 239000000243 solution Substances 0.000 description 87
- 239000000047 product Substances 0.000 description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 239000011541 reaction mixture Substances 0.000 description 65
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 46
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 45
- 239000003208 petroleum Substances 0.000 description 44
- 239000012043 crude product Substances 0.000 description 43
- 238000003818 flash chromatography Methods 0.000 description 43
- 239000002904 solvent Substances 0.000 description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 239000006174 pH buffer Substances 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 32
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 31
- 208000018737 Parkinson disease Diseases 0.000 description 31
- 238000009472 formulation Methods 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- 102000001253 Protein Kinase Human genes 0.000 description 28
- 108060006633 protein kinase Proteins 0.000 description 28
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 27
- 239000012074 organic phase Substances 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 25
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- 125000006239 protecting group Chemical group 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 239000012267 brine Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 18
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 17
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 17
- 239000003446 ligand Substances 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 13
- 229960000583 acetic acid Drugs 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- 239000007821 HATU Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 12
- 102000010111 Ezrin/radixin/moesin Human genes 0.000 description 11
- 108050001788 Ezrin/radixin/moesin Proteins 0.000 description 11
- 102100027869 Moesin Human genes 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 108010071525 moesin Proteins 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 238000005191 phase separation Methods 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000012799 strong cation exchange Methods 0.000 description 7
- 229910052723 transition metal Inorganic materials 0.000 description 7
- 150000003624 transition metals Chemical class 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229910003446 platinum oxide Inorganic materials 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 108020001580 protein domains Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- RLLPVAHGXHCWKJ-IEBWSBKVSA-N (3-phenoxyphenyl)methyl (1s,3s)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(Cl)Cl)[C@@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-IEBWSBKVSA-N 0.000 description 4
- NZYBILDYPCVNMU-NSHDSACASA-N (3r)-3-phenylpiperidine Chemical compound C1CCNC[C@H]1C1=CC=CC=C1 NZYBILDYPCVNMU-NSHDSACASA-N 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000007848 Bronsted acid Substances 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000272186 Falco columbarius Species 0.000 description 4
- 241001444201 Falco tinnunculus Species 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 4
- 108091006109 GTPases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
- 240000007472 Leucaena leucocephala Species 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 208000027089 Parkinsonian disease Diseases 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 230000004853 protein function Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 241000400611 Eucalyptus deanei Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102220577899 Leucine-rich repeat serine/threonine-protein kinase 2_G2019S_mutation Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 3
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 238000012207 quantitative assay Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- SDXMFHWBWDBSKR-UHFFFAOYSA-N 1-(2,4-dichloropyridin-3-yl)ethanone Chemical compound CC(=O)C1=C(Cl)C=CN=C1Cl SDXMFHWBWDBSKR-UHFFFAOYSA-N 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 2
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 2
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GWBHJHIZHNTJLA-UHFFFAOYSA-N 2,4-dichloropyridine-3-carbaldehyde Chemical compound ClC1=CC=NC(Cl)=C1C=O GWBHJHIZHNTJLA-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- FPEKOKIMAJMGBM-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]propan-1-ol Chemical compound C=12C(CCCO)=NNC2=CC=NC=1NC1CCCCC1 FPEKOKIMAJMGBM-UHFFFAOYSA-N 0.000 description 2
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000224495 Dictyostelium Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- PODPAWQSGZBDKA-UHFFFAOYSA-N methyl 4-[2-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 PODPAWQSGZBDKA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000007932 molded tablet Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000005229 pyrazolopyridines Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-BYPYZUCNSA-N (2S)-butan-2-ol Chemical compound CC[C@H](C)O BTANRVKWQNVYAZ-BYPYZUCNSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- IBTSWKLSEOGJGJ-UHFFFAOYSA-N (3-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC(B(O)O)=C1 IBTSWKLSEOGJGJ-UHFFFAOYSA-N 0.000 description 1
- JEGMWWXJUXDNJN-ZCFIWIBFSA-N (3r)-3-methylpiperidine Chemical compound C[C@@H]1CCCNC1 JEGMWWXJUXDNJN-ZCFIWIBFSA-N 0.000 description 1
- NZYBILDYPCVNMU-LLVKDONJSA-N (3s)-3-phenylpiperidine Chemical compound C1CCNC[C@@H]1C1=CC=CC=C1 NZYBILDYPCVNMU-LLVKDONJSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- SHMRFMIXGNQVAU-UHFFFAOYSA-N (4-methoxyphenyl)-[4-[(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC(NC=2C=3C(C)=NNC=3C=CN=2)CC1 SHMRFMIXGNQVAU-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- BZRMCNUYEOEBOG-VOTSOKGWSA-N (e)-3-(4-cyclohexyloxy-2h-pyrazolo[4,3-c]pyridin-3-yl)prop-2-enoic acid Chemical compound C=12C(/C=C/C(=O)O)=NNC2=CC=NC=1OC1CCCCC1 BZRMCNUYEOEBOG-VOTSOKGWSA-N 0.000 description 1
- CTVGMBQRAFLHIY-BUHFOSPRSA-N (e)-3-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]-n,n-dimethylprop-2-enamide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(\C=C\C(=O)N(C)C)=N1 CTVGMBQRAFLHIY-BUHFOSPRSA-N 0.000 description 1
- QXNDZOPVNUAONG-BQYQJAHWSA-N (e)-3-[4-methoxy-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]prop-2-enoic acid Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(OC)=C2C(\C=C\C(O)=O)=N1 QXNDZOPVNUAONG-BQYQJAHWSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DNLWSCOBNDPEOM-UHFFFAOYSA-N 1-(2,4-dichloropyridin-3-yl)ethanol Chemical compound CC(O)C1=C(Cl)C=CN=C1Cl DNLWSCOBNDPEOM-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NNRUOSDIRFGTAX-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3-methyl-n-piperidin-4-ylpyrazolo[4,3-c]pyridin-4-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCNCC3)=C2C(C)=N1 NNRUOSDIRFGTAX-UHFFFAOYSA-N 0.000 description 1
- ZYHZNQNCDMBUMQ-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3-methylpyrazolo[4,3-c]pyridine-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(C#N)=C2C(C)=N1 ZYHZNQNCDMBUMQ-UHFFFAOYSA-N 0.000 description 1
- IPGSCHSDNOBXGU-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3-methylpyrazolo[4,3-c]pyridine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(C(O)=O)=C2C(C)=N1 IPGSCHSDNOBXGU-UHFFFAOYSA-N 0.000 description 1
- GVSCNAOZDQCWJJ-UHFFFAOYSA-N 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(N2N=CC=C2)=C1 GVSCNAOZDQCWJJ-UHFFFAOYSA-N 0.000 description 1
- BAFSQQRPOTVBRS-UHFFFAOYSA-N 1-[4-(cyclohexylamino)-1h-pyrazolo[4,3-c]pyridin-3-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=NNC2=CC=NC(NC3CCCCC3)=C12 BAFSQQRPOTVBRS-UHFFFAOYSA-N 0.000 description 1
- NYHOUSXRLJIMGH-UHFFFAOYSA-N 1-[4-[(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1NC1=NC=CC2=C1C(C)=NN2 NYHOUSXRLJIMGH-UHFFFAOYSA-N 0.000 description 1
- WTCBQACGLUKXHJ-UHFFFAOYSA-N 1-[4-[2-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]ethyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 WTCBQACGLUKXHJ-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- SYZVQXIUVGKCBJ-UHFFFAOYSA-N 1-ethenyl-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(C=C)=C1 SYZVQXIUVGKCBJ-UHFFFAOYSA-N 0.000 description 1
- YFZHODLXYNDBSM-UHFFFAOYSA-N 1-ethenyl-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(C=C)C=C1 YFZHODLXYNDBSM-UHFFFAOYSA-N 0.000 description 1
- FWBDUAPLKFBELK-UHFFFAOYSA-N 1-fluoro-2-nitro-4-phenylmethoxybenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(OCC=2C=CC=CC=2)=C1 FWBDUAPLKFBELK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- PYOFNPHTKBSXOM-UHFFFAOYSA-N 1-methylindazol-5-amine Chemical compound NC1=CC=C2N(C)N=CC2=C1 PYOFNPHTKBSXOM-UHFFFAOYSA-N 0.000 description 1
- MOGQNVSKBCVIPW-UHFFFAOYSA-N 1-methylpyrazol-3-amine Chemical compound CN1C=CC(N)=N1 MOGQNVSKBCVIPW-UHFFFAOYSA-N 0.000 description 1
- UZRXHHMTKCJKTQ-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-ol Chemical compound CC(C)N1CCC(O)CC1 UZRXHHMTKCJKTQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WCXFPLXZZSWROM-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical class C1=NC=C2C=NNC2=C1 WCXFPLXZZSWROM-UHFFFAOYSA-N 0.000 description 1
- TYPVHTOETJVYIV-UHFFFAOYSA-N 2,4-dichloropyridine Chemical compound ClC1=CC=NC(Cl)=C1 TYPVHTOETJVYIV-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- MRNQFRADJPXGJY-UHFFFAOYSA-N 2-(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)-1,3-oxazole Chemical compound C=12C(C)=NNC2=CC=NC=1C1=NC=CO1 MRNQFRADJPXGJY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- GNWJOKCBQBLGJD-INIZCTEOSA-N 3-(4-methoxy-2h-pyrazolo[4,3-c]pyridin-3-yl)-1-[(3r)-3-phenylpiperidin-1-yl]propan-1-one Chemical compound C1([C@H]2CCCN(C2)C(=O)CCC2=NNC=3C=CN=C(C2=3)OC)=CC=CC=C1 GNWJOKCBQBLGJD-INIZCTEOSA-N 0.000 description 1
- BTXVPMQMWWMGKS-UHFFFAOYSA-N 3-(5-aminopyridin-3-yl)benzonitrile Chemical compound NC1=CN=CC(C=2C=C(C=CC=2)C#N)=C1 BTXVPMQMWWMGKS-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FZHJWZHQIOYZAC-UHFFFAOYSA-N 3-(furan-3-yl)-1,5-dihydropyrazolo[4,3-c]pyridin-4-one Chemical compound C1=2C(O)=NC=CC=2NN=C1C=1C=COC=1 FZHJWZHQIOYZAC-UHFFFAOYSA-N 0.000 description 1
- KUDORYBAVLXRAP-UHFFFAOYSA-N 3-[2-(3-aminophenyl)ethyl]-n-cyclohexyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound NC1=CC=CC(CCC=2C3=C(NC4CCCCC4)N=CC=C3NN=2)=C1 KUDORYBAVLXRAP-UHFFFAOYSA-N 0.000 description 1
- NSWDFYDQVXFQME-UHFFFAOYSA-N 3-[2-(4-aminophenyl)ethyl]-n-cyclohexyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(N)=CC=C1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 NSWDFYDQVXFQME-UHFFFAOYSA-N 0.000 description 1
- YNBBTDISMMWTLR-HNNXBMFYSA-N 3-[3-oxo-3-[(3R)-3-phenylpiperidin-1-yl]propyl]-2,5-dihydropyrazolo[4,3-c]pyridin-4-one Chemical compound C1([C@H]2CCCN(C2)C(=O)CCC2=NNC=3C=CN=C(C2=3)O)=CC=CC=C1 YNBBTDISMMWTLR-HNNXBMFYSA-N 0.000 description 1
- JFQYSAUAKKJRLD-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]-n,n-dimethylpropanamide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC(=O)N(C)C)=N1 JFQYSAUAKKJRLD-UHFFFAOYSA-N 0.000 description 1
- BHILGIWKDVCLJI-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]propan-1-ol Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCCO)=N1 BHILGIWKDVCLJI-UHFFFAOYSA-N 0.000 description 1
- IWBCFAVOHFIOBC-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC(O)=O)=N1 IWBCFAVOHFIOBC-UHFFFAOYSA-N 0.000 description 1
- MPXCFNZVXYBJPZ-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]-n,n-dimethylpropanamide Chemical compound C=12C(CCC(=O)N(C)C)=NNC2=CC=NC=1NC1CCCCC1 MPXCFNZVXYBJPZ-UHFFFAOYSA-N 0.000 description 1
- SKIPMEUZCZEBBQ-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]-n-methylpropanamide Chemical compound C=12C(CCC(=O)NC)=NNC2=CC=NC=1NC1CCCCC1 SKIPMEUZCZEBBQ-UHFFFAOYSA-N 0.000 description 1
- LQMQZRZTLMZXCD-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]propanoic acid Chemical compound C=12C(CCC(=O)O)=NNC2=CC=NC=1NC1CCCCC1 LQMQZRZTLMZXCD-UHFFFAOYSA-N 0.000 description 1
- KGDWVAFPGRMMGM-QFIPXVFZSA-N 3-[4-chloro-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]-1-[(3r)-3-phenylpiperidin-1-yl]propan-1-one Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(Cl)=C2C(CCC(=O)N2C[C@H](CCC2)C=2C=CC=CC=2)=N1 KGDWVAFPGRMMGM-QFIPXVFZSA-N 0.000 description 1
- BFVFAXXGCIJUHH-UHFFFAOYSA-N 3-[4-chloro-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(Cl)=C2C(CCC(O)=O)=N1 BFVFAXXGCIJUHH-UHFFFAOYSA-N 0.000 description 1
- IMKYMFYQLHDMAP-QHCPKHFHSA-N 3-[4-methoxy-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]-1-[(3r)-3-phenylpiperidin-1-yl]propan-1-one Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(OC)=C2C(CCC(=O)N2C[C@H](CCC2)C=2C=CC=CC=2)=N1 IMKYMFYQLHDMAP-QHCPKHFHSA-N 0.000 description 1
- CTZAGTLJGOBGEJ-UHFFFAOYSA-N 3-bromo-4-chloro-2h-pyrazolo[4,3-c]pyridine Chemical compound ClC1=NC=CC2=C1C(Br)=NN2 CTZAGTLJGOBGEJ-UHFFFAOYSA-N 0.000 description 1
- YVZTWJHKOYPIIN-UHFFFAOYSA-N 3-bromo-n-cyclohexyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(Br)=NNC2=CC=NC=1NC1CCCCC1 YVZTWJHKOYPIIN-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- LRAYRYFHOKFVJH-UHFFFAOYSA-N 3-methyl-4-(1-methylpyrazol-4-yl)-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(C)=NNC2=CC=NC=1C=1C=NN(C)C=1 LRAYRYFHOKFVJH-UHFFFAOYSA-N 0.000 description 1
- HOVFSVNCZQBOGU-UHFFFAOYSA-N 3-methyl-4-(1-propan-2-ylpiperidin-4-yl)oxy-2h-pyrazolo[4,3-c]pyridine Chemical compound C1CN(C(C)C)CCC1OC1=NC=CC2=NNC(C)=C12 HOVFSVNCZQBOGU-UHFFFAOYSA-N 0.000 description 1
- ZJWBFWMICQCFIG-UHFFFAOYSA-N 3-methyl-4-(3-methylbutyl)-2h-pyrazolo[4,3-c]pyridine Chemical compound CC(C)CCC1=NC=CC2=C1C(C)=NN2 ZJWBFWMICQCFIG-UHFFFAOYSA-N 0.000 description 1
- UDVBLDPEYISFRN-UHFFFAOYSA-N 3-methyl-4-(oxan-4-yloxy)-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(C)=NNC2=CC=NC=1OC1CCOCC1 UDVBLDPEYISFRN-UHFFFAOYSA-N 0.000 description 1
- DIMPDQYNFSHKOP-UHFFFAOYSA-N 3-methyl-n-(1-methylindazol-5-yl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=C2N(C)N=CC2=CC(NC=2N=CC=C3NN=C(C=23)C)=C1 DIMPDQYNFSHKOP-UHFFFAOYSA-N 0.000 description 1
- JBOUFVXXZFTNKF-UHFFFAOYSA-N 3-methyl-n-(1-methylpyrazol-3-yl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NC=1C=CN(C)N=1 JBOUFVXXZFTNKF-UHFFFAOYSA-N 0.000 description 1
- HGUDNTJNXWWTRM-UHFFFAOYSA-N 3-methyl-n-(2-pyridin-2-ylethyl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NCCC1=CC=CC=N1 HGUDNTJNXWWTRM-UHFFFAOYSA-N 0.000 description 1
- JMNUYENPXPLSBU-UHFFFAOYSA-N 3-methyl-n-(oxan-4-yl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NC1CCOCC1 JMNUYENPXPLSBU-UHFFFAOYSA-N 0.000 description 1
- URLLSFWQQBNJGJ-UHFFFAOYSA-N 3-methyl-n-[4-(1,2,4-triazol-1-yl)phenyl]-2h-pyrazolo[4,3-c]pyridin-4-amine;hydrochloride Chemical compound Cl.C=12C(C)=NNC2=CC=NC=1NC(C=C1)=CC=C1N1C=NC=N1 URLLSFWQQBNJGJ-UHFFFAOYSA-N 0.000 description 1
- RSAWMSUQLKKXDN-UHFFFAOYSA-N 3-n,3-n-dimethyl-1-n-(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)benzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(NC=2C=3C(C)=NNC=3C=CN=2)=C1 RSAWMSUQLKKXDN-UHFFFAOYSA-N 0.000 description 1
- HHSBHVJQXZLIRW-UHFFFAOYSA-N 3-n,3-n-dimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(N)=C1 HHSBHVJQXZLIRW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- TZOFSDNBBFFIRA-UHFFFAOYSA-N 3-propylpiperidin-4-ol Chemical compound CCCC1CNCCC1O TZOFSDNBBFFIRA-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- BLNPEJXSNSBBNM-UHFFFAOYSA-N 4-(1,2,4-triazol-1-yl)aniline Chemical compound C1=CC(N)=CC=C1N1N=CN=C1 BLNPEJXSNSBBNM-UHFFFAOYSA-N 0.000 description 1
- YLZVQZXADWVYLP-UHFFFAOYSA-N 4-(4-imidazol-1-ylphenoxy)-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(C)=NNC2=CC=NC=1OC(C=C1)=CC=C1N1C=CN=C1 YLZVQZXADWVYLP-UHFFFAOYSA-N 0.000 description 1
- XIAHDAHNVKDUHO-UHFFFAOYSA-N 4-(5-aminopyridin-3-yl)benzonitrile Chemical compound NC1=CN=CC(C=2C=CC(=CC=2)C#N)=C1 XIAHDAHNVKDUHO-UHFFFAOYSA-N 0.000 description 1
- CBIFHOMBWYBUTI-UHFFFAOYSA-N 4-(furan-2-yl)-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(C)=NNC2=CC=NC=1C1=CC=CO1 CBIFHOMBWYBUTI-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- OJPINBXQDFJZPR-ZETCQYMHSA-N 4-[(2s)-butan-2-yl]oxy-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound CC[C@H](C)OC1=NC=CC2=C1C(C)=NN2 OJPINBXQDFJZPR-ZETCQYMHSA-N 0.000 description 1
- FBAPTUAEBQMVEY-UHFFFAOYSA-N 4-[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethyl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CCN2CCOCC2)N=C1 FBAPTUAEBQMVEY-UHFFFAOYSA-N 0.000 description 1
- GWSJLYHWTLYEKJ-UHFFFAOYSA-N 4-[2-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]ethyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 GWSJLYHWTLYEKJ-UHFFFAOYSA-N 0.000 description 1
- MBCGQYUUPQSYBB-UHFFFAOYSA-N 4-[4-(cyclohexylamino)-1h-pyrazolo[4,3-c]pyridin-3-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=NNC2=CC=NC(NC3CCCCC3)=C12 MBCGQYUUPQSYBB-UHFFFAOYSA-N 0.000 description 1
- CJGJYONRHVIAIF-UHFFFAOYSA-N 4-[5-[(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)amino]pyridin-3-yl]benzonitrile Chemical compound C=12C(C)=NNC2=CC=NC=1NC(C=1)=CN=CC=1C1=CC=C(C#N)C=C1 CJGJYONRHVIAIF-UHFFFAOYSA-N 0.000 description 1
- WADDCOJZSBKBFM-UHFFFAOYSA-N 4-[[1-[(4-methoxyphenyl)methyl]-3-methylpyrazolo[4,3-c]pyridin-4-yl]amino]benzoic acid Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC=3C=CC(=CC=3)C(O)=O)=C2C(C)=N1 WADDCOJZSBKBFM-UHFFFAOYSA-N 0.000 description 1
- BEFKCSGSEJIZRG-UHFFFAOYSA-N 4-benzyl-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(C)=NNC2=CC=NC=1CC1=CC=CC=C1 BEFKCSGSEJIZRG-UHFFFAOYSA-N 0.000 description 1
- GNMHCRJCRCSCBR-UHFFFAOYSA-N 4-chloro-1-[(4-methoxyphenyl)methyl]-3-methylpyrazolo[4,3-c]pyridine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(Cl)=C2C(C)=N1 GNMHCRJCRCSCBR-UHFFFAOYSA-N 0.000 description 1
- FUXZQGSDRGDYGX-UHFFFAOYSA-N 4-chloro-1h-pyrazolo[4,3-c]pyridine Chemical compound ClC1=NC=CC2=C1C=NN2 FUXZQGSDRGDYGX-UHFFFAOYSA-N 0.000 description 1
- MXMHFRXWEXJZOK-UHFFFAOYSA-N 4-chloro-3-cyclopropyl-2h-pyrazolo[4,3-c]pyridine Chemical compound C1=2C(Cl)=NC=CC=2NN=C1C1CC1 MXMHFRXWEXJZOK-UHFFFAOYSA-N 0.000 description 1
- LTPHGFLBWHINDY-UHFFFAOYSA-N 4-chloro-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(Cl)=C2C(I)=N1 LTPHGFLBWHINDY-UHFFFAOYSA-N 0.000 description 1
- GNEBCKDLSGJWKO-UHFFFAOYSA-N 4-chloro-3-iodo-1-tritylpyrazolo[4,3-c]pyridine Chemical compound N1=C(I)C=2C(Cl)=NC=CC=2N1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GNEBCKDLSGJWKO-UHFFFAOYSA-N 0.000 description 1
- PBVPGWHQJRFJQU-UHFFFAOYSA-N 4-chloro-3-iodo-2h-pyrazolo[4,3-c]pyridine Chemical compound ClC1=NC=CC2=C1C(I)=NN2 PBVPGWHQJRFJQU-UHFFFAOYSA-N 0.000 description 1
- WNAUKNSRJZNLPE-UHFFFAOYSA-N 4-chloro-3-methyl-1-tritylpyrazolo[4,3-c]pyridine Chemical compound C12=CC=NC(Cl)=C2C(C)=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WNAUKNSRJZNLPE-UHFFFAOYSA-N 0.000 description 1
- KDNYASYYYCLBOA-UHFFFAOYSA-N 4-chloro-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound C1=NC(Cl)=C2C(C)=NNC2=C1 KDNYASYYYCLBOA-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- ZAJDWGYNMXZROW-UHFFFAOYSA-N 4-cyclohexyloxy-3-(furan-3-yl)-1-tritylpyrazolo[4,3-c]pyridine Chemical compound C1CCCCC1OC1=NC=CC2=C1C(C1=COC=C1)=NN2C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ZAJDWGYNMXZROW-UHFFFAOYSA-N 0.000 description 1
- BPNYWJJIFGVHCG-UHFFFAOYSA-N 4-cyclohexyloxy-3-(furan-3-yl)-1h-pyrazolo[4,3-c]pyridine Chemical compound C1CCCCC1OC1=NC=CC2=C1C(C1=COC=C1)=NN2 BPNYWJJIFGVHCG-UHFFFAOYSA-N 0.000 description 1
- NLKKXPRHZNYOEC-UHFFFAOYSA-N 4-cyclohexyloxy-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(OC3CCCCC3)=C2C(I)=N1 NLKKXPRHZNYOEC-UHFFFAOYSA-N 0.000 description 1
- QGMUYYNDGGUQNZ-UHFFFAOYSA-N 4-cyclohexyloxy-3-iodo-1-tritylpyrazolo[4,3-c]pyridine Chemical compound C=12C(I)=NN(C(C=3C=CC=CC=3)(C=3C=CC=CC=3)C=3C=CC=CC=3)C2=CC=NC=1OC1CCCCC1 QGMUYYNDGGUQNZ-UHFFFAOYSA-N 0.000 description 1
- KLIJAJITWBPUHK-UHFFFAOYSA-N 4-cyclohexyloxy-3-iodo-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(I)=NNC2=CC=NC=1OC1CCCCC1 KLIJAJITWBPUHK-UHFFFAOYSA-N 0.000 description 1
- SZWNAVSPEUVUHU-UHFFFAOYSA-N 4-cyclohexyloxy-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound C=12C(C)=NNC2=CC=NC=1OC1CCCCC1 SZWNAVSPEUVUHU-UHFFFAOYSA-N 0.000 description 1
- SAVORVAQVQNIKX-UHFFFAOYSA-N 4-cyclohexyloxy-3-pyrrolidin-1-yl-1-tritylpyrazolo[4,3-c]pyridine Chemical compound C1CCCN1C1=NN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C2=CC=NC(OC3CCCCC3)=C12 SAVORVAQVQNIKX-UHFFFAOYSA-N 0.000 description 1
- RCMKQXAZSQSITJ-UHFFFAOYSA-N 4-cyclohexyloxy-3-pyrrolidin-1-yl-1h-pyrazolo[4,3-c]pyridine Chemical compound C1CCCN1C1=NNC2=CC=NC(OC3CCCCC3)=C12 RCMKQXAZSQSITJ-UHFFFAOYSA-N 0.000 description 1
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
- OERZHHDOKLCGJB-UHFFFAOYSA-N 4-ethoxy-3-methyl-2h-pyrazolo[4,3-c]pyridine Chemical compound CCOC1=NC=CC2=C1C(C)=NN2 OERZHHDOKLCGJB-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- LVOASPZGXNAHJI-UHFFFAOYSA-N 4-imidazol-1-ylaniline Chemical compound C1=CC(N)=CC=C1N1C=NC=C1 LVOASPZGXNAHJI-UHFFFAOYSA-N 0.000 description 1
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- CLORSOZNZOMECF-HOMQSWHASA-N CC1=NNC2=C1C(=NC=C2)O[C@@H]2CC[C@H](CC2)C Chemical compound CC1=NNC2=C1C(=NC=C2)O[C@@H]2CC[C@H](CC2)C CLORSOZNZOMECF-HOMQSWHASA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 102100020903 Ezrin Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 101100021877 Homo sapiens LRRK2 gene Proteins 0.000 description 1
- 101000941877 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101150081013 LRRK2 gene Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102100032656 Leucine-rich repeat serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 102220578292 Leucine-rich repeat serine/threonine-protein kinase 2_D1994A_mutation Human genes 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 102100022127 Radixin Human genes 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- JOJXAOPYFRETLM-UHFFFAOYSA-N [4-[2-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]ethyl]phenyl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C(C=C1)=CC=C1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 JOJXAOPYFRETLM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- ORTPUEQOLRPPOB-UHFFFAOYSA-N cyclobutyl-[4-[(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C=12C(C)=NNC2=CC=NC=1NC(CC1)CCN1C(=O)C1CCC1 ORTPUEQOLRPPOB-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- PXZJHHSLKYXEAK-UHFFFAOYSA-N cyclopropyl-(2,4-dichloropyridin-3-yl)methanol Chemical compound ClC=1C=CN=C(Cl)C=1C(O)C1CC1 PXZJHHSLKYXEAK-UHFFFAOYSA-N 0.000 description 1
- GXKYIDYFORHEED-UHFFFAOYSA-N cyclopropyl-(2,4-dichloropyridin-3-yl)methanone Chemical compound ClC1=CC=NC(Cl)=C1C(=O)C1CC1 GXKYIDYFORHEED-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical group ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- HQLZFBUAULNEGP-UHFFFAOYSA-N hexan-3-amine Chemical compound CCCC(N)CC HQLZFBUAULNEGP-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000002766 lissamine green dye Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- UHNSRFWQBVXBSK-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid Chemical compound OC.OC(=O)C(F)(F)F UHNSRFWQBVXBSK-UHFFFAOYSA-N 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- ZIZLELXQIGJHTA-OUKQBFOZSA-N methyl (e)-3-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]prop-2-enoate Chemical compound C12=CC=NC(NC3CCCCC3)=C2C(/C=C/C(=O)OC)=NN1CC1=CC=C(OC)C=C1 ZIZLELXQIGJHTA-OUKQBFOZSA-N 0.000 description 1
- SMTIIOWTMPUWQB-BQYQJAHWSA-N methyl (e)-3-[4-chloro-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]prop-2-enoate Chemical compound C12=CC=NC(Cl)=C2C(/C=C/C(=O)OC)=NN1CC1=CC=C(OC)C=C1 SMTIIOWTMPUWQB-BQYQJAHWSA-N 0.000 description 1
- RAQDJGGMFYCUEF-UHFFFAOYSA-N methyl 3-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]propanoate Chemical compound C=12C(CCC(=O)OC)=NNC2=CC=NC=1NC1CCCCC1 RAQDJGGMFYCUEF-UHFFFAOYSA-N 0.000 description 1
- IXRUWMUTCFZKCI-UHFFFAOYSA-N methyl 3-[4-chloro-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]propanoate Chemical compound C12=CC=NC(Cl)=C2C(CCC(=O)OC)=NN1CC1=CC=C(OC)C=C1 IXRUWMUTCFZKCI-UHFFFAOYSA-N 0.000 description 1
- DNPOAIPCGPHBGM-SFQUDFHCSA-N methyl 4-[(e)-2-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]ethenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1\C=C\C(C1=C(NC2CCCCC2)N=CC=C11)=NN1CC1=CC=C(OC)C=C1 DNPOAIPCGPHBGM-SFQUDFHCSA-N 0.000 description 1
- IMWQOFFASQFNKG-UHFFFAOYSA-N methyl 4-[2-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCC(C1=C(NC2CCCCC2)N=CC=C11)=NN1CC1=CC=C(OC)C=C1 IMWQOFFASQFNKG-UHFFFAOYSA-N 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- NUMHUJZXKZKUBN-UHFFFAOYSA-N methyl 4-ethenylbenzoate Chemical compound COC(=O)C1=CC=C(C=C)C=C1 NUMHUJZXKZKUBN-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- QANFWZBOAAFADW-UHFFFAOYSA-N n'-[3-[4-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-3-yl]propanoyl]benzohydrazide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC(=O)NNC(=O)C=2C=CC=CC=2)=N1 QANFWZBOAAFADW-UHFFFAOYSA-N 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- SCNKXDIHWQFDDC-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-3-methyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NC(CC1)CCN1CC1=CC=CC=C1 SCNKXDIHWQFDDC-UHFFFAOYSA-N 0.000 description 1
- LXMIMRIGYVEFSW-UHFFFAOYSA-N n-(2-fluorophenyl)-3-methyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NC1=CC=CC=C1F LXMIMRIGYVEFSW-UHFFFAOYSA-N 0.000 description 1
- WIUCZHCPJFKBHO-UHFFFAOYSA-N n-(3-chlorophenyl)-3-methyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NC1=CC=CC(Cl)=C1 WIUCZHCPJFKBHO-UHFFFAOYSA-N 0.000 description 1
- UDJCWTNANHEHSI-UHFFFAOYSA-N n-(3-fluorophenyl)-1h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound FC1=CC=CC(NC=2C=3C=NNC=3C=CN=2)=C1 UDJCWTNANHEHSI-UHFFFAOYSA-N 0.000 description 1
- WMHNXUFHISRONS-UHFFFAOYSA-N n-[(2,4-dimethoxyphenyl)methyl]-3-methyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=CC2=C1C(C)=NN2 WMHNXUFHISRONS-UHFFFAOYSA-N 0.000 description 1
- ONQCVWNDKNOILT-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-3-methyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NCC1=CC=C(Cl)C=C1 ONQCVWNDKNOILT-UHFFFAOYSA-N 0.000 description 1
- KNDXLEZGDWYFJW-UHFFFAOYSA-N n-[3-[2-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]ethyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(CCC=2C3=C(NC4CCCCC4)N=CC=C3NN=2)=C1 KNDXLEZGDWYFJW-UHFFFAOYSA-N 0.000 description 1
- JRYZFDJFXRINAM-UHFFFAOYSA-N n-[3-[4-(cyclohexylamino)-1h-pyrazolo[4,3-c]pyridin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C3=C(NC4CCCCC4)N=CC=C3NN=2)=C1 JRYZFDJFXRINAM-UHFFFAOYSA-N 0.000 description 1
- KZQZTUKDAYFAOY-UHFFFAOYSA-N n-[4-[2-[4-(cyclohexylamino)-2h-pyrazolo[4,3-c]pyridin-3-yl]ethyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 KZQZTUKDAYFAOY-UHFFFAOYSA-N 0.000 description 1
- JLWBUNWRDPTCIT-UHFFFAOYSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-(2-phenylethyl)pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC=2C=CC=CC=2)=N1 JLWBUNWRDPTCIT-UHFFFAOYSA-N 0.000 description 1
- KIFVCPSMHNZFSH-UHFFFAOYSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-(2-piperidin-4-ylethyl)pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC2CCNCC2)=N1 KIFVCPSMHNZFSH-UHFFFAOYSA-N 0.000 description 1
- GTOSJWWUCOFLDC-UHFFFAOYSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-(2-pyridin-2-ylethyl)pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC=2N=CC=CC=2)=N1 GTOSJWWUCOFLDC-UHFFFAOYSA-N 0.000 description 1
- NNAZYQMWBRAPLF-UHFFFAOYSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-(2-pyridin-4-ylethyl)pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC=2C=CN=CC=2)=N1 NNAZYQMWBRAPLF-UHFFFAOYSA-N 0.000 description 1
- YBUCMGGNXDFLGE-UHFFFAOYSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-(3-pyrazol-1-ylphenyl)pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(C=2C=C(C=CC=2)N2N=CC=C2)=N1 YBUCMGGNXDFLGE-UHFFFAOYSA-N 0.000 description 1
- QKVHNHUENUVEFA-NTCAYCPXSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-[(e)-2-(3-nitrophenyl)ethenyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(\C=C\C=2C=C(C=CC=2)[N+]([O-])=O)=N1 QKVHNHUENUVEFA-NTCAYCPXSA-N 0.000 description 1
- OQJHUWSLIXVIAY-LFIBNONCSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-[(e)-2-(4-nitrophenyl)ethenyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(\C=C\C=2C=CC(=CC=2)[N+]([O-])=O)=N1 OQJHUWSLIXVIAY-LFIBNONCSA-N 0.000 description 1
- ZIBWOPLRYCWHSE-SAPNQHFASA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-[(e)-2-phenylethenyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(\C=C\C=2C=CC=CC=2)=N1 ZIBWOPLRYCWHSE-SAPNQHFASA-N 0.000 description 1
- FXWLRVCLJYCXGC-NTCAYCPXSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-[(e)-2-pyridin-2-ylethenyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(\C=C\C=2N=CC=CC=2)=N1 FXWLRVCLJYCXGC-NTCAYCPXSA-N 0.000 description 1
- CWKIAXYCMYIETI-FMIVXFBMSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-[(e)-2-pyridin-4-ylethenyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(\C=C\C=2C=CN=CC=2)=N1 CWKIAXYCMYIETI-FMIVXFBMSA-N 0.000 description 1
- ZFKVMBODGUNYGH-UHFFFAOYSA-N n-cyclohexyl-1-[(4-methoxyphenyl)methyl]-3-[2-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(CCC=2OC(=NN=2)C=2C=CC=CC=2)=N1 ZFKVMBODGUNYGH-UHFFFAOYSA-N 0.000 description 1
- XCIGCBBRXPDLQQ-UHFFFAOYSA-N n-cyclohexyl-1h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CCCCC1NC1=NC=CC2=C1C=NN2 XCIGCBBRXPDLQQ-UHFFFAOYSA-N 0.000 description 1
- QRPPHQPDTBCBDB-UHFFFAOYSA-N n-cyclohexyl-3-(2-phenylethyl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound N=1NC2=CC=NC(NC3CCCCC3)=C2C=1CCC1=CC=CC=C1 QRPPHQPDTBCBDB-UHFFFAOYSA-N 0.000 description 1
- QRJWQFITEUGXEO-UHFFFAOYSA-N n-cyclohexyl-3-(2-piperidin-4-ylethyl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CNCCC1CCC(C=12)=NNC2=CC=NC=1NC1CCCCC1 QRJWQFITEUGXEO-UHFFFAOYSA-N 0.000 description 1
- RYWGOHGFJAGDRM-UHFFFAOYSA-N n-cyclohexyl-3-(2-pyridin-2-ylethyl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound N=1NC2=CC=NC(NC3CCCCC3)=C2C=1CCC1=CC=CC=N1 RYWGOHGFJAGDRM-UHFFFAOYSA-N 0.000 description 1
- CVLBZAYYOHSMGH-UHFFFAOYSA-N n-cyclohexyl-3-(2-pyridin-4-ylethyl)-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound N=1NC2=CC=NC(NC3CCCCC3)=C2C=1CCC1=CC=NC=C1 CVLBZAYYOHSMGH-UHFFFAOYSA-N 0.000 description 1
- GYLMPSIUBIJUKX-MDZDMXLPSA-N n-cyclohexyl-3-[(e)-2-(3-nitrophenyl)ethenyl]-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound [O-][N+](=O)C1=CC=CC(\C=C\C=2C3=C(NC4CCCCC4)N=CC=C3NN=2)=C1 GYLMPSIUBIJUKX-MDZDMXLPSA-N 0.000 description 1
- YGFCBCZPMTUPLB-DHZHZOJOSA-N n-cyclohexyl-3-[(e)-2-(4-nitrophenyl)ethenyl]-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=NNC2=CC=NC(NC3CCCCC3)=C12 YGFCBCZPMTUPLB-DHZHZOJOSA-N 0.000 description 1
- LQTOTADUJHQONL-VOTSOKGWSA-N n-cyclohexyl-3-[(e)-2-pyridin-4-ylethenyl]-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CCCCC1NC1=NC=CC2=C1C(\C=C\C=1C=CN=CC=1)=NN2 LQTOTADUJHQONL-VOTSOKGWSA-N 0.000 description 1
- IQXQQNKHAXREMZ-UHFFFAOYSA-N n-cyclohexyl-3-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]-1h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1COCCN1CCN(N=C1)C=C1C(C=12)=NNC2=CC=NC=1NC1CCCCC1 IQXQQNKHAXREMZ-UHFFFAOYSA-N 0.000 description 1
- ABXJEKUMMNMZFW-UHFFFAOYSA-N n-cyclohexyl-3-[2-(1-methylsulfonylpiperidin-4-yl)ethyl]-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CN(S(=O)(=O)C)CCC1CCC1=NNC2=CC=NC(NC3CCCCC3)=C12 ABXJEKUMMNMZFW-UHFFFAOYSA-N 0.000 description 1
- SPDDSVMMLFIQDI-UHFFFAOYSA-N n-cyclohexyl-3-[2-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound N=1N=C(C=2C=CC=CC=2)OC=1CCC(C=12)=NNC2=CC=NC=1NC1CCCCC1 SPDDSVMMLFIQDI-UHFFFAOYSA-N 0.000 description 1
- SLHXAMODMOMLFE-OAQYLSRUSA-N n-cyclohexyl-3-[3-[(3s)-3-phenylpiperidin-1-yl]propyl]-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1([C@@H]2CCCN(C2)CCCC=2C3=C(NC4CCCCC4)N=CC=C3NN=2)=CC=CC=C1 SLHXAMODMOMLFE-OAQYLSRUSA-N 0.000 description 1
- IGPOYFLGORZELQ-UHFFFAOYSA-N n-cyclohexyl-3-cyclopropyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CC1C1=NNC2=CC=NC(NC3CCCCC3)=C12 IGPOYFLGORZELQ-UHFFFAOYSA-N 0.000 description 1
- OWUAEWCNRLBBNN-UHFFFAOYSA-N n-cyclohexyl-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCCCC3)=C2C(I)=N1 OWUAEWCNRLBBNN-UHFFFAOYSA-N 0.000 description 1
- NTHVCYRZMWBAGI-UHFFFAOYSA-N n-cyclohexyl-3-methyl-2h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C=12C(C)=NNC2=CC=NC=1NC1CCCCC1 NTHVCYRZMWBAGI-UHFFFAOYSA-N 0.000 description 1
- GIUIZQIVJYKFMI-UHFFFAOYSA-N n-cyclohexyl-3-methyl-2h-pyrazolo[4,3-c]pyridine-4-carboxamide Chemical compound C=12C(C)=NNC2=CC=NC=1C(=O)NC1CCCCC1 GIUIZQIVJYKFMI-UHFFFAOYSA-N 0.000 description 1
- XWMDRBBRZWMPHP-UHFFFAOYSA-N n-cyclohexyl-3-phenyl-1h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CCCCC1NC1=NC=CC2=C1C(C=1C=CC=CC=1)=NN2 XWMDRBBRZWMPHP-UHFFFAOYSA-N 0.000 description 1
- AHSJGZGPXSOVQF-UHFFFAOYSA-N n-cyclohexyl-3-pyridin-3-yl-1h-pyrazolo[4,3-c]pyridin-4-amine Chemical compound C1CCCCC1NC1=NC=CC2=C1C(C=1C=NC=CC=1)=NN2 AHSJGZGPXSOVQF-UHFFFAOYSA-N 0.000 description 1
- MQQIWQIHDIGEOF-UHFFFAOYSA-N n-cyclopentyl-4-[(3-methyl-2h-pyrazolo[4,3-c]pyridin-4-yl)amino]benzamide Chemical compound C=12C(C)=NNC2=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1CCCC1 MQQIWQIHDIGEOF-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 108010048484 radixin Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- MQELQPIWLDELCL-UHFFFAOYSA-N tert-butyl 4-[[1-[(4-methoxyphenyl)methyl]-3-methylpyrazolo[4,3-c]pyridin-4-yl]amino]piperidine-1-carboxylate Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=NC(NC3CCN(CC3)C(=O)OC(C)(C)C)=C2C(C)=N1 MQELQPIWLDELCL-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- IRDLREGHQZFMKF-ZHACJKMWSA-N tert-butyl 4-cyclohexyloxy-3-[(e)-3-methoxy-3-oxoprop-1-enyl]pyrazolo[4,3-c]pyridine-1-carboxylate Chemical compound C=12C(/C=C/C(=O)OC)=NN(C(=O)OC(C)(C)C)C2=CC=NC=1OC1CCCCC1 IRDLREGHQZFMKF-ZHACJKMWSA-N 0.000 description 1
- SBUWGNDUPXWHHP-UHFFFAOYSA-N tert-butyl 4-cyclohexyloxy-3-iodopyrazolo[4,3-c]pyridine-1-carboxylate Chemical compound N1=CC=C2N(C(=O)OC(C)(C)C)N=C(I)C2=C1OC1CCCCC1 SBUWGNDUPXWHHP-UHFFFAOYSA-N 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- YOWGRWHKDCHINP-UHFFFAOYSA-N tributyl(1,3-oxazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CO1 YOWGRWHKDCHINP-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- WRSWIWOVJBYZAW-UHFFFAOYSA-M zinc;methanidylbenzene;bromide Chemical compound Br[Zn+].[CH2-]C1=CC=CC=C1 WRSWIWOVJBYZAW-UHFFFAOYSA-M 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0904746A GB0904746D0 (en) | 2009-03-19 | 2009-03-19 | Compounds |
| GB0904746.5 | 2009-03-19 | ||
| US16202409P | 2009-03-20 | 2009-03-20 | |
| US61/162,024 | 2009-03-20 | ||
| GB0912238A GB0912238D0 (en) | 2009-07-14 | 2009-07-14 | Compounds |
| GB0912238.3 | 2009-07-14 | ||
| GBGB1001418.1A GB201001418D0 (en) | 2010-01-28 | 2010-01-28 | Compounds |
| GB1001418.1 | 2010-01-28 | ||
| PCT/GB2010/000498 WO2010106333A1 (en) | 2009-03-19 | 2010-03-19 | Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520861A JP2012520861A (ja) | 2012-09-10 |
| JP2012520861A5 JP2012520861A5 (https=) | 2013-02-28 |
| JP5732036B2 true JP5732036B2 (ja) | 2015-06-10 |
Family
ID=42226628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500308A Expired - Fee Related JP5732036B2 (ja) | 2009-03-19 | 2010-03-19 | 化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20100317646A1 (https=) |
| EP (1) | EP2408772B1 (https=) |
| JP (1) | JP5732036B2 (https=) |
| KR (1) | KR101700229B1 (https=) |
| CN (1) | CN102428084B (https=) |
| AU (1) | AU2010224693B2 (https=) |
| CA (1) | CA2754605C (https=) |
| CL (1) | CL2011002267A1 (https=) |
| IL (1) | IL215147A0 (https=) |
| MX (1) | MX2011009807A (https=) |
| PE (1) | PE20120506A1 (https=) |
| RU (1) | RU2011142182A (https=) |
| WO (1) | WO2010106333A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2451676C2 (ru) * | 2006-08-16 | 2012-05-27 | Ф.Хоффманн-Ля Рош Аг | Ненуклеозидные ингибиторы обратной транскриптазы |
| GB201008134D0 (en) * | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| US9233977B2 (en) * | 2010-10-29 | 2016-01-12 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| US20130338106A1 (en) * | 2011-02-28 | 2013-12-19 | John A. McCauley | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US8791112B2 (en) | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| AU2012244549B2 (en) * | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| RU2637936C2 (ru) * | 2011-05-23 | 2017-12-08 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
| CN102558174B (zh) * | 2011-08-23 | 2014-03-19 | 天津市斯芬克司药物研发有限公司 | 一种全新吡唑并[4,3-c]吡啶化合物的发明及其合成方法 |
| HUE029728T2 (en) * | 2011-09-30 | 2017-03-28 | Ipsen Pharma Sas | Macrocyclic LRRK2 kinase inhibitors |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2013182612A1 (en) | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| EP2867236B1 (en) * | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| ES2661585T3 (es) * | 2012-10-31 | 2018-04-02 | Raqualia Pharma Inc | Derivados de pirazolopiridina como bloqueadores de TTX-S |
| AU2013343105B2 (en) * | 2012-11-08 | 2016-04-14 | Pfizer Inc. | Heteroaromatic compounds as dopamine D1 ligands |
| WO2014150981A1 (en) * | 2013-03-15 | 2014-09-25 | Elan Pharmaceuticals, Llc | Inhibitors of lrrk2 kinase activity |
| US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| TW201534597A (zh) | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
| US9718818B2 (en) * | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| KR20170002623A (ko) | 2014-05-14 | 2017-01-06 | 화이자 인코포레이티드 | 피라졸로피리딘 및 피라졸로피리미딘 |
| EP3190889B1 (en) | 2014-09-03 | 2021-11-17 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| US10918645B2 (en) | 2016-06-15 | 2021-02-16 | Lifearc | Substituted tricyclic heterocyclic compounds and use thereof |
| KR101923852B1 (ko) | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| KR101990738B1 (ko) * | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| JP2023504623A (ja) * | 2019-12-04 | 2023-02-06 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤 |
| KR20230026479A (ko) | 2020-06-22 | 2023-02-24 | 에프. 호프만-라 로슈 아게 | 설폰 유도체 |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| KR20240144325A (ko) * | 2022-02-25 | 2024-10-02 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 융합 고리 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835144A (en) * | 1972-06-16 | 1974-09-10 | Squibb & Sons Inc | Amino derivatives of (4,3-c pyrazolopyridine cabroxylic acids and esters |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US5478830A (en) * | 1992-05-29 | 1995-12-26 | The Du Pont Merck Pharmaceutical Company | Fused-ring heterocycles for the treatment of atherosclerosis |
| US5300478A (en) * | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| US7429609B2 (en) * | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| EP1545515A1 (en) * | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| WO2005016875A2 (en) * | 2003-08-06 | 2005-02-24 | Sugen, Inc. | Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors |
| WO2005121094A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
| WO2006009245A1 (ja) * | 2004-07-23 | 2006-01-26 | Tanabe Seiyaku Co., Ltd. | 含窒素縮合二環式化合物 |
| PE20061119A1 (es) | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP1989330A4 (en) * | 2006-01-31 | 2009-10-21 | Elan Pharm Inc | ALPHA-SYNUCLEINE KINASE |
| US20100273776A1 (en) * | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| NZ591115A (en) * | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
| GB201015949D0 (en) * | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
-
2010
- 2010-03-19 EP EP10711443.1A patent/EP2408772B1/en not_active Not-in-force
- 2010-03-19 RU RU2011142182/04A patent/RU2011142182A/ru unknown
- 2010-03-19 CA CA2754605A patent/CA2754605C/en not_active Expired - Fee Related
- 2010-03-19 JP JP2012500308A patent/JP5732036B2/ja not_active Expired - Fee Related
- 2010-03-19 AU AU2010224693A patent/AU2010224693B2/en not_active Ceased
- 2010-03-19 WO PCT/GB2010/000498 patent/WO2010106333A1/en not_active Ceased
- 2010-03-19 PE PE2011001662A patent/PE20120506A1/es not_active Application Discontinuation
- 2010-03-19 KR KR1020117024068A patent/KR101700229B1/ko not_active Expired - Fee Related
- 2010-03-19 MX MX2011009807A patent/MX2011009807A/es not_active Application Discontinuation
- 2010-03-19 CN CN201080021866.0A patent/CN102428084B/zh active Active
- 2010-03-19 US US12/727,754 patent/US20100317646A1/en not_active Abandoned
-
2011
- 2011-09-13 CL CL2011002267A patent/CL2011002267A1/es unknown
- 2011-09-14 IL IL215147A patent/IL215147A0/en unknown
-
2017
- 2017-04-03 US US15/478,141 patent/US20170320870A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2754605C (en) | 2018-04-17 |
| CN102428084A (zh) | 2012-04-25 |
| PE20120506A1 (es) | 2012-05-14 |
| KR101700229B1 (ko) | 2017-01-26 |
| IL215147A0 (en) | 2011-12-29 |
| US20170320870A1 (en) | 2017-11-09 |
| RU2011142182A (ru) | 2013-04-27 |
| CA2754605A1 (en) | 2010-09-23 |
| EP2408772B1 (en) | 2015-07-01 |
| CN102428084B (zh) | 2016-05-18 |
| MX2011009807A (es) | 2011-09-29 |
| EP2408772A1 (en) | 2012-01-25 |
| KR20110128925A (ko) | 2011-11-30 |
| JP2012520861A (ja) | 2012-09-10 |
| AU2010224693A1 (en) | 2011-09-15 |
| WO2010106333A1 (en) | 2010-09-23 |
| CL2011002267A1 (es) | 2012-05-11 |
| AU2010224693B2 (en) | 2016-07-28 |
| US20100317646A1 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5732036B2 (ja) | 化合物 | |
| JP2013529196A (ja) | キナーゼｌｒｒｋ２の阻害剤としてのピラゾロピリジン | |
| US8569281B2 (en) | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | |
| AU2013242492B2 (en) | Bicyclic pyrazinone derivatives | |
| CN100376580C (zh) | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 | |
| KR20060120393A (ko) | 글리코겐 신타아제 키나제 3 저해제로서의트리아졸로피리미딘 유도체 | |
| CA2931249A1 (en) | Pyrrolopyrrolone derivatives and their use as bet inhibitors | |
| CN106795152B (zh) | 蛋白激酶抑制剂 | |
| AU2016355103B2 (en) | Pyrropyrimidine compounds as MNKs inhibitors | |
| JP2024528729A (ja) | Ｓｒｐｋインヒビター | |
| HK1260037B (zh) | 取代的三环杂环化合物及其用途 | |
| HK40006420A (zh) | 治疗性抑制化合物 | |
| HK1260037A1 (en) | Substituted tricyclic herteocyclic compounds and use thereof | |
| EA041461B1 (ru) | Ингибиторы тирозинкиназы брутона | |
| HK1203961B (en) | Bicyclic pyrazinone derivatives | |
| TW201427979A (zh) | 含氮雜環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140526 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140926 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150312 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150410 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5732036 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |